Jules Mitchel of Target Health discusses risk-based monitoring trends in the clinical trials industry
Jules Mitchel of Target Health discusses, his views on its importance of risk-based monitoring in the clinical trials industry, now that is such a popular topic.
- Increasing Intensity of On-Site Monitoring a Troubling Trend
- Industry Metric Indicates Low ROI with Full Source Document Verification
- Has FDA Guidance on Risk-based Monitoring Impacted SDV Coverage Yet?More in Risk-Based Monitoring